Skip to content

Study Evaluating the Clinical Remission in Early Aggressive Rheumatoid Arthritis

An Observational Study To Evaluate The Clinical Remission In Early Aggressive Rheumatoid Arthritis (Artrite Reumatoide Precoce Aggressiva Italian Study)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00267852
Acronym
ARPA
Enrollment
152
Registered
2005-12-21
Start date
2006-04-30
Completion date
2010-07-31
Last updated
2011-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Keywords

Arthritis

Brief summary

This is an observational prospective, multicenter study. The aim of the study is to evaluate how the Italian population of patients are treated with early aggressive RA, defined by the Italian Society of Rheumatology Guidelines, (GIARA Registry Study Group. Clin Exp Rheumatol 2003;21(Suppl. 31):S129-S132), in rheumatologic clinical practice and whether recent scientific evidence or new treatments available to rheumatologists can change their practice in a 2 year follow-up. The observation will primarily focus on the disease activity and clinical remission in patients who are receiving different treatment strategies. The primary goal is to define prevalence of clinical remission, according to the (Disease Activity Score) DAS 28 definition of clinical remission, in patients with early aggressive RA receiving different therapies at 1 year. Secondary objective are assessment of: * Prevalence of Remission at the second year * Disease activity at the first and second year. * ACR 20%, 50%, 70% response at the first and second year. * Quality of Life in patients with or without remission at the first and second year * Safety Evaluations

Detailed description

It was expected that approximate 200 patients were enrolled in the study. Have been enrolled 152 patients. A Statistical Analysis Plan will contain a detailed description of criteria for valuable patients for analyses and a description of statistical analyses. In general, all patients who respond inclusion/exclusion criteria at baseline will be considered valuable for the study. The summaries will include descriptive statistics (mean, standard deviation, sample size) for the continuous parameters, and absolute frequencies and percentages for the remaining categorical parameters.

Interventions

OTHERas clinical practice

Dosage, form, frequency and duration as per ordinary clinical practice

Sponsors

Wyeth is now a wholly owned subsidiary of Pfizer
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Inclusion Criteria Based On Clinical Practice of Aggressive RA * Diagnosis of early aggressive RA in accordance with local guideline * Disease duration \< 2 years and at least six months since onset of symptoms * Patients naïve to anti-TNFa drugs and DMARDs, including MTX, or assuming one or more DMARD without complete response

Design outcomes

Primary

MeasureTime frame
Prevalence of clinical remission, according to the DAS 28 definition of clinical remission, in patients with early aggressive RA receiving different therapies at 1 year.12-24 months

Secondary

MeasureTime frame
-Prevalence of Remission at the second year.12-24 months
Disease activity at the 1st and 2nd year12-24 months
ACR 20%, 50%, 70% response at the 1st and 2nd year12-24 months
QoL in patients with or without remission at the first and second year12-24 months
Safety Evaluations12-24 months

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026